Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Erica Secchettin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7924-5577; OpenAlex author ID A5047796715. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
79
Papers, trials and grants by year

2018: 3 papers · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 3 papers

Papers 20

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. First author DOI 10.1002/ueg2.70187↗
  3. Hereditary pancreatic cancer: A proposal for surveillance from the Italian Association for the Study of the Pancreas (AISP). Co-author DOI 10.1016/j.dld.2026.04.007↗
  4. Expert Judgment Supporting a Bayesian Network to Model the Survival of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers17020301↗
  5. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance… Co-author DOI 10.1007/s10689-024-00366-3↗
  6. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. First author DOI 10.1097/sla.0000000000006094↗
  7. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. Co-author DOI 10.1245/s10434-024-14951-4↗
  8. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  9. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  10. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  11. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  12. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy i… Co-author DOI 10.1186/s12885-021-07877-7↗
  13. The emotional impact of surveillance programs for pancreatic cancer on high-risk individuals: A prospective analysis. Co-author DOI 10.1002/pon.5370↗
  14. Italian registry of families at risk of pancreatic cancer: AISP Familial Pancreatic Cancer Study Group. Co-author DOI 10.1016/j.dld.2020.07.027↗
  15. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08515-5↗
  16. PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic Cancer Patients Prior to Major Surgery. Co-author DOI 10.3389/fpsyg.2020.00362↗
  17. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  18. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Co-author DOI 10.1007/s00423-017-1627-0↗
  19. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.hpb.2017.10.017↗
  20. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Salvatore Paiella · 18 shared papers, 2018–2026 · strength 2.75
  2. Roberto Salvia · 17 shared papers, 2018–2026 · strength 2.23
  3. Giuseppe Malleo · 14 shared papers, 2018–2026 · strength 1.82
  4. Claudio Bassi · 14 shared papers, 2018–2024 · strength 1.57
  5. Lívia Archibugi · 6 shared papers, 2024–2026 · strength 1.26
  6. Fabio Casciani · 6 shared papers, 2019–2025 · strength 1.10
  7. Gabriele Capurso · 6 shared papers, 2020–2026 · strength 1.03
  8. Massimo Falconi · 6 shared papers, 2020–2026 · strength 1.03
  9. Silvia Carrara · 5 shared papers, 2020–2026 · strength 1.02
  10. Matteo De Pastena · 8 shared papers, 2018–2026 · strength 1.01
  11. Gabriella Lionetto · 5 shared papers, 2021–2026 · strength 0.81
  12. Raffaele De Luca · 3 shared papers, 2026 · strength 0.73
  13. Darío Gregori · 4 shared papers, 2023–2025 · strength 0.71
  14. Alessandro Zerbi · 5 shared papers, 2020–2026 · strength 0.71
  15. Paolo Giorgio Arcidiacono · 4 shared papers, 2024–2026 · strength 0.67
  16. Claudio Ricci · 4 shared papers, 2023–2026 · strength 0.57
  17. Marta Puzzono · 3 shared papers, 2024–2026 · strength 0.50
  18. Giuliana Sereni · 3 shared papers, 2024–2026 · strength 0.50
  19. Arianna Dal Buono · 3 shared papers, 2024–2026 · strength 0.50
  20. Giulia Martina Cavestro · 3 shared papers, 2024–2026 · strength 0.50
  21. Laura Maggino · 5 shared papers, 2018–2023 · strength 0.48
  22. Michèle Milella · 4 shared papers, 2020–2023 · strength 0.45
  23. Carlo Ingaldi · 3 shared papers, 2023–2026 · strength 0.44
  24. Giovanni Butturini · 3 shared papers, 2020–2026 · strength 0.43
  25. Riccardo Casadei · 3 shared papers, 2023–2024 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.